Louis Gendron is an associate professor in the faculty of medicine and health sciences at Université de Sherbrooke. He oversees the pain research axis at the Centre de recherche clinique Étienne-Le Bel du CHUS and the university's graduate programs in physiology. He is also an active member of the Institut de pharmacologie de Sherbrooke, the Québec Pain Research Network and the executive committee of the International Narcotics Research Conference.
In 2003, Mr. Gendron earned his PhD in physiology from Université de Sherbrooke and went on to complete two postdoctoral training programs at McGill University and the University of Washington in Seattle.
His research is chiefly focused on the biomolecular characteristics of the delta opioid receptors (DOR) involved in pain modulation in humans and animals in an effort to better understand the roles, regulation and mechanisms of action of DOR with regards to pain. The young researcher aims to establish the therapeutic value of selective delta agonists in the treatment of chronic pain (e.g. arthritis, bone cancer) so as to develop new therapies.
Mr. Gendron recently distinguished himself when he demonstrated the significant analgesic effects of DOR and implemented an animal platform to explore whether selective delta antagonists have analgesic, antianxiety and antidepressant properties in animals suffering from chronic pain.